What Is Poria (Fu Ling)? One of the Most Important Mushrooms in TCM

Poria (Wolfiporia extensa / Fu Ling)

159 triterpenoids

Wolfiporia extensa contains 159 catalogued triterpenoids, and its polysaccharide was approved as a prescription drug in China in 2015. Most Western consumer health sites still file the evidence under 'insufficient.'

Xiong et al., Frontiers in Pharmacology, 2025

73 RCTs

in the largest Poria diabetes meta-analysis

2,500 years

of documented medicinal use

2015

Chinese FDA drug approval year

Xiong et al., Frontiers in Pharmacology, 2025

View as image ↗

Most Western consumer health sites file poria mushroom under "insufficient evidence." Meanwhile, the published literature contains 73 randomized controlled trials of TCM formulas containing Poria for type 2 diabetes alone. A 2022 meta-analysis pooled all 73 of them — 6,489 participants — and found that adding these formulas to standard glucose-lowering drugs reduced fasting blood glucose by 0.82 mmol/L and HbA1c by 0.64 percentage points versus the drugs alone.^[1] A separate review documented that China's drug regulator had approved a Poria polysaccharide oral solution as a prescription drug in 2015, for multiple cancers, hepatitis and other conditions, used either alone or alongside chemotherapy and radiotherapy.^[2]

The evidence is not missing. It has simply not crossed the language and attention barriers of most English-language health writing. As the rest of this article shows, "not missing" is also not the same as "strong" — the Poria literature has a specific and uneven shape, and the honest version of the story includes where it thins out.

Poria (Wolfiporia extensa), known in Chinese medicine as Fu Ling and in older Latin pharmacopoeia as Poria cocos, is among the ten most frequently prescribed herbs in China for type 2 diabetes and a mainstay of the wider Chinese medicine system.^[1] Its medicinal portion is a dense underground mass called a sclerotium, which forms on the roots of pine trees. It looks nothing like a typical mushroom cap. Researchers have catalogued 159 distinct triterpenoids in the species, while polysaccharides account for roughly 84% of its active ingredients by weight.^[3]

This article covers what poria mushroom is, what is actually inside it, why the three different preparations sold as Fu Ling have different clinical uses, how the active compounds work at the molecular level, and what the human clinical evidence shows.

What Is Poria Mushroom? (The Short Answer)

Poria (Wolfiporia extensa), known in Chinese medicine as Fu Ling, is a wood-decay fungus whose underground sclerotium has been used medicinally for over 2,500 years. Unlike most mushrooms, it grows as a dense, potato-shaped mass on pine tree roots rather than as a cap-and-stem fruiting body. It contains two main classes of active compounds: pachyman, a structural polysaccharide (beta-glucan) that activates immune cells in laboratory studies, and pachymic acid, a triterpene that suppresses inflammation and, in rodent work, acts on the brain's GABA signalling system. A 2011 comprehensive review by Ríos established this dual-compound profile as the foundational pharmacological framework for the species.^[4]

From "Superior Grade" Herb in 200 AD to Chinese Prescription Drug in 2015

Classical Chinese pharmacology organized medicinal substances into three grades. Superior-grade herbs (shang pin) were those considered safe for long-term daily use without toxicity, the only category implying that conclusion. Poria's placement in that top tier, first documented in the Shen Nong Ben Cao Jing around 200 AD, defined how Chinese physicians used it for the next two millennia: not as an emergency intervention but as a tonic, added to formulas for chronic conditions requiring sustained support. A 2025 Journal of Ethnopharmacology review integrating the full historical record with modern pharmacological data confirmed how consistent this clinical application has been across those centuries.^[5]

Over 2,000 years, Poria became embedded in some of the most widely prescribed formulas in the Chinese medicine system. Si Jun Zi Tang (Four Gentlemen Decoction) uses it for Spleen qi deficiency, understood in modern terms as digestive weakness, chronic low energy, and impaired nutrient absorption. Ling Gui Zhu Gan Tang uses it for what TCM describes as water accumulation with Heart Yang deficiency, a pattern that overlaps with fluid retention and cardiac fatigue. Gui Zhi Fu Ling Wan pairs it with cinnamon twig and red peony for blood stasis; this formula remains in active clinical use in Chinese gynecology today. Zhu Ling Tang incorporates it into formulas for damp-heat patterns, particularly urinary tract conditions.

The modern regulatory milestone came quietly. In 2015, the Chinese Food and Drug Administration approved Polysaccharidum of Poria cocos oral solution as a prescription drug for treating multiple types of cancer, hepatitis and other diseases — either on its own or during chemotherapy or radiotherapy. The same product had already been sold as an over-the-counter health supplement since the 1970s. A 2019 review summarised the biochemical, preclinical and clinical record behind it: 74 independent studies spanning 46 years, from 1970 to 2018.^[2]

Two caveats belong next to that fact, because it is the single most over-claimed detail about Poria online. First, drug approval in China does not imply approval anywhere else, and the Chinese regulatory standard for traditional-medicine-derived products is not equivalent to an FDA or EMA new-drug approval. Second, the approval covers one specific manufactured oral solution — it is not a judgment about Poria powders, capsules or teas sold elsewhere, which are regulated as foods or supplements and are not that product. What the 2015 approval does show is that a regulator reviewed a substantial body of evidence and judged it sufficient for prescription use, which is a meaningfully different situation from "no evidence exists."

Fact Check

'Poria is an FDA-approved cancer drug'

The claim

“Poria polysaccharide is an approved cancer drug, so its anti-cancer benefits are officially proven.”

Supplement marketing compressing 'approved by the Chinese FDA in 2015 for use alongside chemotherapy' into 'FDA-approved cancer drug.'

What research shows

Misleading

The 2015 approval was granted by the Chinese Food and Drug Administration, not the US FDA, for a polysaccharide oral solution used for multiple cancers, hepatitis and other diseases — alone or during chemotherapy or radiotherapy.

It is a real regulatory decision informed by a literature of 74 studies spanning 1970–2018, and it is not nothing. But it applies to one specific manufactured oral solution in one jurisdiction, it does not transfer to the over-the-counter Poria powders and capsules sold elsewhere, and it is not evidence that Poria treats cancer on its own.

Li et al., Progress in Molecular Biology and Translational Science, 2019 (RTHM-01090)

For a detailed examination of each classical formula, its TCM indications, and the modern pharmacological mechanisms that explain its clinical use, see Fu Ling in Traditional Chinese Medicine: 2,000 Years of Use.

Two Compound Families, 159 Catalogued Triterpenoids — What Poria Actually Contains

The chemistry of Poria divides cleanly into two families that operate through largely separate mechanisms.

Polysaccharides: The Immune-Activating Majority

The dominant polysaccharide is pachyman, a beta-glucan built on a (1→3)-β-D-glucan backbone with (1→6) branch points. Polysaccharides as a class account for roughly 84% of Poria's active ingredients by weight, making them the bulk of what a water extract delivers.^[3] Poria polysaccharide is the component the 2015 Chinese drug approval was built on, and the compound with the deepest preclinical and clinical record of anything in the mushroom.^[6]

Native pachyman has a practical problem: it is poorly water-soluble, which limits how much of it a simple decoction can actually extract. A companion polysaccharide called pachymaran shares the same basic architecture but is smaller and more water-soluble. Chemically modified versions of pachyman — sulfated or carboxymethylated in laboratory settings — are more soluble again and show enhanced immune activation compared to the native compound, which is why Poria polysaccharide derivatives, rather than raw pachyman, are the pharmaceutical research candidates.

Triterpenoids: The Anti-Inflammatory Minority

If polysaccharides dominate by quantity, triterpenoids account for the pharmacological depth. A 2025 Frontiers in Pharmacology review classified 159 distinct triterpenoids reported from Wolfiporia extensa, predominantly tetracyclic lanostane-type structures, making Poria one of the more chemically complex medicinal fungi studied to date.^[3] Counts vary by review and by how strictly compounds are counted: a 2025 Journal of Ethnopharmacology review put the figure at 120.^[5] The 2011 Ríos phytochemical review established the primary triterpene acid categories: pachymic acid, tumulosic acid, and the poricoic acids, each with distinct activity profiles.^[4] A 2020 Frontiers in Pharmacology review summarised the pharmacological range attributed to Poria's two main compound classes: anti-tumor, anti-bacterial, antioxidant, anti-inflammatory, immunomodulatory, and liver- and kidney-protective activities.^[7]

Pachymic acid is the most extensively studied triterpenoid. It suppresses inflammation through the NF-κB pathway, the molecular switch controlling inflammatory gene expression — demonstrated directly in a rat model of LPS-induced pneumonia, where pachymic acid reduced inflammation and cell death by acting on NF-κB and MAPK signalling.^[13] In mice, it also acts on the GABAergic system that sedative drugs target, which is the mechanistic thread behind Poria's traditional calming use.^[12] Both of those results come from animal models, not people.

The poricoic acids deserve a separate note. They are characteristic of Poria and are the compound class most closely tied to its kidney-related research: poricoic acid A and its relatives are studied for anti-fibrotic activity in models of chronic kidney disease.^[3] A 2007 study also found triterpene acids from Poria, including poricoic acid derivatives, showed anti-tumor-promoting activity in laboratory assays, making them a candidate class for cancer-preventive research.^[14]

Why Extraction Method Determines What You Actually Get

Hot water extraction concentrates Poria's polysaccharides (pachyman, pachymaran). Ethanol extraction concentrates its triterpenoids (pachymic acid, poricoic acids). A dual extraction captures both compound classes. Most commercial Poria supplements use hot water extraction standardized for polysaccharide content.

This is not a technicality — it determines whether a product matches the research behind the claim on its label. The immune and blood-sugar evidence runs through polysaccharides, which favours water extraction. The sleep and anti-inflammatory mechanisms run through triterpenoids, which favours ethanol. It is worth noting that the one human sleep study used a 75% ethanol extract, meaning a hot-water Poria powder is not the preparation that produced that result.^[9] The full breakdown of each compound class and how extraction choices affect bioavailability is covered in Poria Bioactive Compounds: Pachymic Acid, Triterpenoids, and Beta-Glucans.

Bai Fu Ling, Fu Shen, and Chi Fu Ling: Three Parts of the Same Fungus, Three Clinical Uses

This is the distinction almost universally absent from supplement labels, health websites, and English-language coverage of Poria, but it matters for anyone reading classical formula translations or evaluating products that specify preparation type.

The Poria sclerotium has three pharmacologically distinct zones. Traditional Chinese pharmacy treats each as a separate medicine with different primary indications.

Bai Fu Ling (White Poria). The inner white flesh of the sclerotium, dried and cut into slices or cubes. This is the preparation found in most modern supplements and used in most published research. Its classical indication targets the Spleen and Stomach (the digestive system in TCM terms), addressing dampness accumulation, poor appetite, loose stools, and fatigue from impaired nutrient absorption. This is the polysaccharide-rich portion of the sclerotium, which lines up with the immune and metabolic activity attributed to Poria polysaccharides in pharmacological research.^[5]

Fu Shen (Spirit Poria, or Pine-Heart Poria). The portion of the sclerotium that grew directly around a pine root, cut to show the embedded wood fragment. Classical texts distinguish Fu Shen specifically for its action on the Heart organ in TCM, the seat of consciousness and emotional stability. It was prescribed for palpitations, insomnia driven by emotional distress, excessive dreaming, and anxiety. The pachymic acid work in mice — where it enhanced sleeping behaviour through GABAergic systems — gives Fu Shen's classical calming indication a plausible molecular thread.^[12] What that thread does not yet include is a study comparing Fu Shen against bai fu ling in humans, or a published phytochemical analysis establishing that the cortex zone is meaningfully richer in triterpenoids. The traditional distinction is documented; its chemical basis is asserted more often than it is measured.

Chi Fu Ling (Red Poria). The dark reddish outer skin of the sclerotium, separated and dried. Classical practice treats it as a distinct medicine from the inner flesh, and it appears primarily in formulas for Blood pattern disorders, particularly Gui Zhi Fu Ling Wan for gynecological blood stasis conditions. As with Fu Shen, the traditional differentiation is well documented in the pharmacopoeia, but comparative phytochemical data quantifying how the outer skin differs from the inner sclerotium is thin in the English-language literature.

When a supplement label reads "Poria cocos extract" without further specification, it almost certainly contains bai fu ling. If a product specifies "fu shen," it should include the pine root fraction. These three preparations are not interchangeable within the classical system — but a reader should hold the traditional distinction and the state of the chemical evidence separately. The first is millennia old and consistently applied; the second is genuinely underdeveloped.

Three Preparations · Traditional Indication vs Modern Evidence Reach

One fungus, three medicines — but only one of them has been studied

Traditional Chinese pharmacy treats the three zones of the Poria sclerotium as separate medicines with different primary indications. That distinction is real, ancient and consistently documented. What follows it in most write-ups is an implication that modern research has validated each zone separately. It has not.

Bai Fu Ling白茯苓 · White Poria[1] [5]Used in human studies

Part used: Inner white flesh of the sclerotium

Classical indication

Spleen and Stomach: dampness accumulation, poor appetite, loose stools, fatigue from impaired absorption.

What modern research covers

This is effectively the only preparation in the modern record. The polysaccharide research, the 2015 Chinese drug approval and the 73-trial diabetes meta-analysis all run through the inner flesh or extracts of it. It is also what almost every supplement labelled "Poria cocos extract" contains.

Fu Shen茯神 · Spirit Poria[9] [12]Compound evidence only

Part used: The zone that grew around an embedded pine root

Classical indication

Heart: palpitations, insomnia driven by emotional distress, excessive dreaming, anxiety.

What modern research covers

The calming indication has a plausible mechanism — pachymic acid acts on GABAergic systems in mice — but that is evidence about a compound found throughout the sclerotium, not about Fu Shen specifically. No human trial has tested Fu Shen, and no published analysis establishes that the cortex zone carries meaningfully more triterpenoid than the inner flesh.

Chi Fu Ling赤茯苓 · Red Poria[5]No modern evidence

Part used: Dark reddish outer skin, separated and dried

Classical indication

Blood patterns, notably within Gui Zhi Fu Ling Wan for gynaecological blood stasis.

What modern research covers

The classical differentiation is well documented in the pharmacopoeia and the formula tradition. Comparative phytochemistry quantifying how the outer skin differs from the inner sclerotium is largely absent from the English-language literature, and no clinical study isolates this preparation.

This is not an argument that the classical distinctions are wrong. Two thousand years of consistent clinical differentiation is a serious form of evidence, and the 2025 Lei review names the qualitative and quantitative analysis of Poria’s active ingredients as an open problem rather than a settled one. It is an argument that a product trading on Fu Shen’s calming reputation is borrowing authority from a tradition, not from a trial.

Sources: Di et al. (2022); Lei et al. (2025); Kim et al. (2023); Shah et al. (2014)

View as image ↗

How Poria Works: Two Independent Molecular Pathways

The pharmacology of Poria runs through two largely parallel mechanisms driven by two different compound classes. Understanding both explains why Poria appears in clinical formulas for conditions as different as cancer adjuvant treatment, blood sugar regulation, and insomnia.

The Immune Pathway: Polysaccharides Activating Macrophages

Macrophages are the immune system's primary surveillance and response cells. They patrol tissues, engulf pathogens and damaged cells, and coordinate other immune responses. In cell culture, isolated Poria polysaccharide fractions activate macrophages by binding a receptor complex on their surface called TLR4/MD2.

A 2024 study by Sun et al. isolated a specific Poria polysaccharide fraction (labeled PCP-W1) and mapped this interaction directly in cultured mouse macrophages. PCP-W1 triggered polarization into the M1 type, the active, pro-inflammatory response mode, causing cells to release nitric oxide, IL-6, IL-1β, TNF-α and reactive oxygen species, and to display the surface marker CD86 that helps recruit other immune cells — all through the TLR4/MD2/NF-κB pathway.^[8]

One detail from that paper is worth correcting a common simplification. PCP-W1 is not a pure beta-glucan: it is built from galactose, glucose, fucose and mannose in roughly a 36:29:22:14 ratio, with a molecular weight of 18.38 kDa. Molecular docking showed it binds the hydrophobic pocket of the TLR4/MD2 complex primarily through its galactose chain, not through the beta-glucan backbone that popular accounts usually credit.^[8] Poria's immune activity is a property of specific isolated fractions with specific structures, not a generic "beta-glucan effect."

In practical terms, Poria polysaccharide does not passively support immune function; in cell culture it actively shifts macrophages into a higher-response state via a specific receptor interaction. In anti-tumor contexts this matters because tumours suppress macrophage activity as a survival mechanism. The caveat is the standard one for this tier of evidence: RAW 264.7 is an immortalised mouse cell line, and molecular docking is a computational prediction. Neither establishes what happens in a person who swallows Poria extract. For a detailed examination of the TLR4/MD2 pathway and what it means for immune health claims, see Poria and Immune Health: Immunomodulatory Research.

The Brain Pathway: Triterpenoids on GABA Receptors

Pachymic acid appears to work through a different system entirely: the brain's GABA signalling, centred on GABA-A receptors. These receptors are the central nervous system's primary braking mechanism. When they are activated, neural firing slows, anxiety decreases, and the conditions for sleep improve. Benzodiazepine drugs also target this receptor family, though at different binding sites. The evidence placing pachymic acid in this system is real but entirely preclinical, and it is more accurately described as modulating GABA signalling than as directly switching the receptor on.

The direct evidence for this comes from a 2014 mouse study by Shah et al., not from a review. Pachymic acid prolonged pentobarbital-induced sleeping time and shortened sleep onset, acting synergistically with muscimol (a known GABA-A agonist). At the protein level it raised GAD65/67, the enzymes that manufacture GABA, and altered GABA-A receptor subunit expression — increasing α and β subunits while decreasing the γ subunit.^[12] That is a real GABAergic mechanism, but note what it is: modulation of the GABA system in rodents, not demonstrated activation of human GABA-A receptors. The subunit changes in particular are a more complicated picture than "pachymic acid switches on the brain's brakes."

Human evidence

Kim, Choi, Park, Ju, Kim (2023) · Nutrients

Population

21 adults with poor sleep quality, mean age 55, South Korea

Intervention

800 mg Poria cocos 75% ethanol extract nightly, assessed by sleep questionnaire and polysomnography

Comparator

None — each participant compared against their own baseline

Finding

Total sleep time rose from 327.4 to 356.5 minutes (p = 0.014) and time spent aroused during sleep fell from 76.3 to 48.0 minutes (p = 0.009), with improvement on the sleep severity index.

preliminary Single-arm and open-label with no control or placebo group, so the roughly 29-minute gain cannot be separated from placebo response, regression to the mean, or simply being monitored in a sleep lab. Directionally encouraging, not confirmatory.

Kim et al., Nutrients, 2023 (RTHM-01720)

Kim et al. tested this in humans in 2023. Twenty-one South Korean adults with poor sleep, mean age 55, took 800 mg of Poria extract nightly; total sleep time and arousal time both improved significantly against their own baselines.^[9] Two things are frequently misreported about this study. It was not randomized and had no placebo arm — it compared each participant to their own baseline using a signed-rank test, which is the weakest design that still counts as a clinical study. And it did not measure GABA-A activity in its participants; the authors discuss pachymic acid as a candidate explanation, but the mechanism comes from the rodent literature, not from this trial. Worth noting for anyone matching a supplement to this result: the extract was prepared with 75% ethanol, a triterpenoid-favouring method, not the hot-water extraction most commercial Poria powders use. For the complete evidence on this indication, see Fu Ling and Insomnia: Sedative Research.

For the full pharmacological picture, including hepatoprotective and metabolic mechanisms, see The Pharmacology of Wolfiporia extensa: How Poria Works.

What 73 Clinical Trials Actually Found

Here is the human clinical evidence for Poria, organized by condition.

Diabetes: The Strongest Clinical Evidence Base

Di et al. published a meta-analysis in PLoS One in 2022 pooling 73 randomized controlled trials — 6,489 participants — of TCM formulas containing Poria cocos for type 2 diabetes.^[1] Adding these formulas on top of standard glucose-lowering drugs reduced fasting blood glucose by 0.82 mmol/L (95% CI −0.93 to −0.71), two-hour postprandial glucose by 1.15 mmol/L, and HbA1c by 0.64 percentage points (95% CI −0.75 to −0.53), with adverse events no higher than in the drug-only group.

Strongest clinical evidence

Di, Sun, Lu, Guo, Tang, Zhang, Fan, Xue (2022) · PLoS One

Population

6,489 people with type 2 diabetes across 73 randomized controlled trials

Intervention

Herbal formulae containing Fuling (Poria) added to hypoglycaemic drug treatment

Comparator

Hypoglycaemic drugs alone

Finding

Fasting blood glucose −0.82 mmol/L, 2-hour postprandial glucose −1.15 mmol/L, HbA1c −0.64 percentage points. Adverse events were not increased.

mixed Large and consistent in direction, but heterogeneity was high (I² = 79.6% for fasting glucose, 84.7% for HbA1c), most trials were judged at risk of bias, and the authors rated overall evidence strength low to moderate. The formulas were multi-herb, so Poria's own contribution is not separable.

Di et al., PLoS One, 2022 (RTHM-01503)

Those effect sizes are clinically meaningful — a 0.64-point HbA1c drop is in the range of adding a second oral diabetes drug. But three limitations sit on top of them, and the original framing of this evidence usually omits all three.

First, heterogeneity was high: I² reached 79.6% for fasting glucose and 84.7% for HbA1c. That means the trials disagreed with each other substantially, and the pooled average conceals a wide spread of individual results rather than summarising a consistent effect. Second, the authors judged most included studies to be at risk of bias and rated the strength of evidence as low to moderate — their conclusion, not an outside critique. Third, the limitation inherent to TCM research design: these were multi-herb formulas, not Poria alone, so Poria's individual contribution cannot be calculated from the pooled data. Poria appeared across enough different formulas and trials to be a consistent contributing variable rather than incidental, but "consistent presence" is not "demonstrated active ingredient."

Cancer Adjuvant Treatment: Regulatory-Level Evidence

Two separate evidence threads exist for Poria in cancer contexts.

First, the 2015 Chinese FDA approval of the Poria polysaccharide oral solution, discussed above, which summarised 74 studies spanning 1970 to 2018.^[2]

Second, a 2022 integrated systems pharmacology study by Peng et al. examined 13 randomized controlled trials (922 patients total) testing Poria cocos-based TCM formulas combined with standard paclitaxel-carboplatin chemotherapy for ovarian cancer. Compared with chemotherapy alone, the combination improved tumour response rate, TCM syndrome score, Karnofsky Performance Scale scores, and physical and social function, while reducing chemotherapy side effects.^[10] The network pharmacology and molecular docking portion of the study pointed to the PI3K/Akt pathway and the gene BCL2L1 as the mechanistic targets, and identified tumulosic acid — not pachymic acid — as the most bioactive Poria compound in this context, with cell experiments confirming it induced apoptosis via PI3K/Akt and BCL2L1.

The same formula-complexity caveat applies here, and one more: these trials were conducted in an adjunct setting alongside conventional chemotherapy. Nothing in this literature supports Poria as a cancer treatment on its own, and the endpoints improved were response rates and quality-of-life measures rather than survival.

Sleep: Early But Direct Human Data

The Kim 2023 study (21 poor sleepers, 800 mg nightly, significant improvements in sleep duration and arousal time) is currently the only published human study testing Poria specifically for sleep outcomes.^[9] It is small, uncontrolled, and single-site. What makes it worth citing is not its strength but its position: it is the first time a traditional indication for Poria, supported by a rodent mechanism, was paired with objective human measurement (polysomnography rather than self-report alone). That is a starting point for a research line, not an answer.

For the broader modern evidence base, including the regulatory approval context and the diabetes meta-analysis numbers in detail, see Poria cocos in Traditional Chinese Medicine: 2,000 Years of Clinical Use.

What the Evidence Doesn't Show Yet

The 2026 Guo et al. narrative update in Frontiers in Nutrition, the most current comprehensive review of Poria pharmacology available, catalogues an expanded profile covering renal protection, digestive function improvement, sleep quality, immune regulation, antioxidant activity, anticancer properties, and glucose-lipid metabolism modulation.^[11] The research base has grown substantially in recent years.

What the evidence does not yet provide:

The clinical data is predominantly from TCM formula trials. This is structural, not a deficiency. TCM formulas are how Poria has been used for 2,500 years and how the clinical database was built. But it means isolating Poria's individual contribution from any single trial is not possible with the current data.

Single-ingredient, placebo-controlled RCTs of Poria are essentially absent. The Kim 2023 sleep study is the closest thing available, and it is neither randomized nor placebo-controlled. This is the largest single gap in the evidence base: for all the mechanistic depth and all the formula-level trial data, there is not one well-controlled trial isolating Poria itself in humans.

Dose-response relationships are largely uncharacterized for most indications in English-language research. The sleep trial used 800 mg nightly of standardized extract. TCM formula studies used varying Poria quantities within complex formulas. No systematic dose-finding work has been published in English for most indications.

This does not describe an absence of evidence. It describes an evidence base with a specific shape: detailed mechanistic work at the molecular level, a regulatory decision supporting polysaccharide activity, substantial formula-based clinical data in diabetes and cancer adjuvant contexts, and almost no single-ingredient controlled trial data. That shape largely reflects where the research has been conducted and how the herb has traditionally been used, rather than a verdict on the underlying biology.

1. Cell studiescompleted

   Extensive. PCP-W1 mapped to the TLR4/MD2/NF-κB pathway in mouse macrophages; tumulosic acid shown to trigger apoptosis via PI3K/Akt and BCL2L1.

2. Animal studiescompleted

   Extensive. Pachymic acid acts on GABAergic systems in mice and suppresses NF-κB/MAPK inflammation in rats; poricoic acids studied in kidney fibrosis models.

3. Traditional clinical recordcompleted

   2,500 years of documented use across four major classical formulas, plus a 2015 Chinese FDA approval for a polysaccharide oral solution.

4. Small human trialscurrent

   Thin. One uncontrolled 21-person sleep study is the only human work on isolated Poria extract.

5. Large single-ingredient RCTsmissing

   None. No adequately powered, placebo-controlled trial has tested Poria on its own for any indication.

6. Meta-analysiscompleted

   Exists, but only of multi-herb formulas: 73 RCTs in diabetes and 13 in ovarian cancer adjunct care — Poria's own contribution is not isolable.

Poria has an unusual evidence profile: deep preclinical mechanism work and formula-level meta-analyses at both ends, with the single-ingredient human trials that would normally connect them almost entirely missing. The meta-analyses sit high on the ladder but test formulas, not Poria.

Di et al. 2022; Peng et al. 2022; Kim et al. 2023; Sun et al. 2024; Shah et al. 2014

Safety

Moderate

Poria formulas were studied alongside diabetes medication, not instead of it

Concern

The diabetes evidence comes from trials where Poria formulas were added on top of prescription glucose-lowering drugs and reduced blood glucose further. Someone taking Poria while on metformin, sulfonylureas or insulin is reproducing that additive setup without the monitoring the trials provided, which raises a plausible risk of hypoglycaemia.

What the research says

Poria's traditional 'superior grade' classification refers to long-term use of the herb itself and says nothing about drug interactions. The Di 2022 analysis found no increase in adverse events overall, but its trials were supervised clinical settings with active glucose monitoring.

Particularly relevant for: People taking glucose-lowering medication, people on diuretics (Poria is traditionally used as a diuretic), pregnant or breastfeeding people, and anyone in active cancer treatment

What to do

Talk to the prescribing clinician before adding Poria to any medication regimen, particularly diabetes or diuretic drugs. This article is research explanation, not medical advice, and nothing here should be used to start, stop or change a treatment.

Di et al., PLoS One, 2022 (RTHM-01503)

The Bottom Line

Poria (Wolfiporia extensa / Fu Ling) has one of the longest documented clinical histories of any medicinal fungus, and a 2015 Chinese FDA approval of a Poria polysaccharide oral solution plus a 2022 meta-analysis of 73 randomized trials put it well beyond the "insufficient evidence" label it usually carries in Western consumer health writing. Its two compound classes work through largely separate pathways: polysaccharides drive macrophage activation via TLR4/MD2/NF-κB in cell studies, while the triterpene pachymic acid suppresses inflammation via NF-κB in rats and acts on GABAergic systems in mice. The best human data covers multi-herb TCM formulas in type 2 diabetes (fasting glucose −0.82 mmol/L, HbA1c −0.64 points, though with high heterogeneity and substantial risk of bias) and as an adjunct to ovarian cancer chemotherapy. The one human study of Poria extract on its own, a 2023 sleep study in 21 adults, was uncontrolled and unrandomized. The accurate summary is neither "insufficient evidence" nor "clinically proven": it is a deeply characterised traditional medicine whose modern research has skipped the single-ingredient controlled trials that would settle what it does in people.

Frequently Asked Questions

Is fu ling the same as poria mushroom?

Yes. Fu Ling is the Chinese medicine name for Wolfiporia extensa, the same fungus sold in Western supplement markets as poria or Poria cocos. The names refer to the same organism: a pine-root-growing, sclerotium-forming wood-decay fungus. Fu Ling is used in traditional Chinese medicine texts and clinical practice; poria and Poria cocos are the names used in Western botanical and supplement contexts.

What does poria mushroom do for the body?

In laboratory studies, Poria's polysaccharides activate macrophages — the immune system's primary patrol and response cells — through the TLR4/MD2/NF-κB pathway (Sun et al., 2024). Its most-studied triterpene, pachymic acid, suppresses inflammatory signalling via NF-κB in rats (Gui et al., 2021) and acts on the brain's GABA system in mice (Shah et al., 2014). In humans, the clearest evidence is indirect: a 2022 meta-analysis of 73 trials found Poria-containing TCM formulas added to diabetes medication lowered fasting glucose by 0.82 mmol/L and HbA1c by 0.64 points (Di et al., 2022). Those trials tested multi-herb formulas, so this is evidence for formulas containing Poria rather than for Poria alone.

Is poria cocos safe to take daily?

The Shen Nong Ben Cao Jing, Chinese medicine's foundational pharmacopoeia, classified Poria as shang pin, the superior grade reserved for herbs considered safe for long-term daily use without toxicity, and that classification has held across 2,500 years of documented use. The 2022 meta-analysis of 73 diabetes trials found adverse events were no more common when Poria formulas were added to medication than with medication alone (Di et al., 2022). What does not exist is a long-term, placebo-controlled safety trial of isolated Poria, so the formal safety profile remains incompletely characterized — and traditional safety classification says nothing about interactions with modern drugs. Anyone taking glucose-lowering or diuretic medication, pregnant or breastfeeding, or in cancer treatment should check with a clinician first. This is general research information, not medical advice.

What is the difference between fu ling and fu shen?

Fu Ling typically refers to bai fu ling: the inner white flesh of the sclerotium, used primarily for Spleen and digestive indications. Fu Shen is the portion of the sclerotium that grew directly around a pine root, used specifically for Heart-related indications: insomnia, palpitations, and anxiety. The GABAergic activity of pachymic acid demonstrated in mice (Shah et al., 2014) offers a plausible molecular thread for Fu Shen's classical calming function, though no study has compared Fu Shen against bai fu ling in humans, and published data quantifying the chemical difference between the two zones is limited. Most supplements labeled "poria" contain bai fu ling, not fu shen.

What is poria used for in Chinese medicine?

In TCM, Poria primarily strengthens the Spleen (digestive system), resolves dampness (fluid accumulation), calms the mind (an shen), and supports the Heart and Kidney meridians. It appears in four major classical formulas: Si Jun Zi Tang for Spleen qi deficiency, Ling Gui Zhu Gan Tang for water accumulation and Heart Yang deficiency, Gui Zhi Fu Ling Wan for blood stasis, and Zhu Ling Tang for damp-heat patterns. A 2025 Journal of Ethnopharmacology review by Lei et al. documented this 2,500-year use history in detail.

What does poria cocos taste like?

Raw poria is largely tasteless and odorless. Classical Chinese medicine describes it as gan dan (sweet-bland), a flavor profile characteristic of herbs that primarily act on the Spleen without a strong taste-based indication. This blandness is one reason Poria has been used as a base ingredient in classical formulas for centuries: it contributes biological activity without dominating the formula's taste. The dried sclerotium has a firm, starchy texture and is finely powdered or sliced for medicinal preparation.

Is poria an adaptogen?

Poria is not typically classified as an adaptogen in the Western framework. Adaptogens are defined by their ability to normalize stress-response physiology, primarily via HPA axis regulation. Poria's primary mechanisms are immune activation via polysaccharides and GABA-A receptor modulation via pachymic acid. The GABA-A activity overlaps with anxiolytic effects but operates through a different mechanism than classic adaptogens like ashwagandha or rhodiola. In TCM, Poria is classified as a qi tonic and shen-calming herb, a category that does not map directly onto the Western adaptogen concept.

How is poria cocos different from reishi?

Both are wood-decay medicinal fungi with immunomodulatory polysaccharides and lanostane triterpenoids. The key differences: reishi (Ganoderma lucidum) grows as an above-ground fruiting body with a distinctive shelf form; poria grows entirely underground as a shapeless sclerotium. Reishi's triterpenoids (ganoderic acids) have been more extensively studied in Western clinical contexts, and reishi has more single-ingredient human trial data. A Poria polysaccharide oral solution reached prescription drug status in China in 2015, which no reishi product has. Poria appears more frequently in classical TCM multi-herb formulas; reishi is more commonly used as a single-ingredient supplement. Their immune mechanisms overlap in that both act on pattern-recognition receptors on macrophages, but the specific fractions and binding details differ.

Sources & References

1. 1RTHM-01503·Di, Yuan Ming et al. (2022). “Benefits of herbal formulae containing Poria cocos (Fuling) for type 2 diabetes mellitus: A systematic review and meta-analysis..” PloS one.Study breakdown →PubMed →↩
2. 2RTHM-01090·Li, Xiulian et al. (2019). “Molecular basis for Poria cocos mushroom polysaccharide used as an antitumor drug in China..” Progress in molecular biology and translational science.Study breakdown →PubMed →↩
3. 3RTHM-02212·Xiong, Qi et al. (2025). “Progress in the study of bioactivity, chemical composition and pharmacological mechanism of action in Wolfiporia cocos (F.A. Wolf) Ryvarden & Gilb..” Frontiers in pharmacology.Study breakdown →PubMed →↩
4. 4RTHM-00431·Ríos, José-Luis (2011). “Chemical constituents and pharmacological properties of Poria cocos..” Planta medica.Study breakdown →PubMed →↩
5. 5RTHM-02126·Lei, Juanhong et al. (2025). “A multidimensional perspective on Poria cocos, an ancient fungal traditional Chinese medicine..” Journal of ethnopharmacology.Study breakdown →PubMed →↩
6. 6RTHM-01091·Li, Xiulian et al. (2019). “Molecular basis for Poria cocos mushroom polysaccharide used as an antitumour drug in China..” Journal of cellular and molecular medicine.Study breakdown →PubMed →↩
7. 7RTHM-01268·Nie, Anzheng et al. (2020). “Phytochemistry and Pharmacological Activities of Wolfiporia cocos (F.A. Wolf) Ryvarden & Gilb..” Frontiers in pharmacology.Study breakdown →PubMed →↩
8. 8RTHM-01999·Sun, Mingjie et al. (2024). “Screening of Poria cocos polysaccharide with immunomodulatory activity and its activation effects on TLR4/MD2/NF-κB pathway..” International journal of biological macromolecules.Study breakdown →PubMed →↩
9. 9RTHM-01720·Kim, Hyeyun et al. (2023). “Efficacy of Poria Cocos Extract on Sleep Quality Enhancement: A Clinical Perspective with Implications for Functional Foods..” Nutrients.Study breakdown →PubMed →↩
10. 10RTHM-01597·Peng, Xinya et al. (2022). “Efficacy and Pharmacological Mechanism of Poria cocos-Based Formulas Combined With Chemotherapy for Ovarian Cancer: A Integrated Systems Pharmacology Study..” Frontiers in pharmacology.Study breakdown →PubMed →↩
11. 11RTHM-02230·Guo, Yanquan et al. (2026). “Research progress on the pharmacological effects of Poria cocos: a narrative update..” Frontiers in nutrition.Study breakdown →PubMed →↩
12. 12RTHM-00641·Shah, Vikash Kumar et al. (2014). “Pachymic Acid Enhances Pentobarbital-Induced Sleeping Behaviors via GABAA-ergic Systems in Mice..” Biomolecules & therapeutics.Study breakdown →PubMed →↩
13. 13RTHM-01360·Gui, Yanjun et al. (2021). “Pachymic acid inhibits inflammation and cell apoptosis in lipopolysaccharide (LPS)-induced rat model with pneumonia by regulating NF-κB and MAPK pathways..” Allergologia et immunopathologia.Study breakdown →PubMed →↩
14. 14RTHM-00205·Akihisa, Toshihiro et al. (2007). “Triterpene acids from Poria cocos and their anti-tumor-promoting effects..” Journal of natural products.Study breakdown →PubMed →↩